Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)

Những quyển sách tương tự

• Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
  Bằng: Doehner, H, et al.
  Được phát hành: (2017)
• Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
  Bằng: Döhner, H, et al.
  Được phát hành: (2018)
• P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
  Bằng: Daniel Lopes De Menezes, et al.
  Được phát hành: (2023-08-01)
• Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
  Bằng: Andrew H. Wei, et al.
  Được phát hành: (2023-03-01)
• Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
  Bằng: DiNardo, C, et al.
  Được phát hành: (2019)